U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297238) titled 'Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.' on Sept. 19.
Brief Summary: Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcom...